1. ATG4B as a novel biomarker for abdominal aortic aneurysm: integrated evaluation through experimental and bioinformatics analyses.
- Author
-
Jing J, Sun Q, Zhang R, Yang C, Yang J, Ma C, and Li T
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Autophagy-Related Proteins genetics, Autophagy-Related Proteins metabolism, Aortic Aneurysm, Abdominal blood, Aortic Aneurysm, Abdominal genetics, Aortic Aneurysm, Abdominal metabolism, Biomarkers blood, Biomarkers metabolism, Cysteine Endopeptidases genetics, Cysteine Endopeptidases blood, Cysteine Endopeptidases metabolism, Computational Biology
- Abstract
Autophagy related gene 4B (ATG4B) plays a central role in autophagy machinery, but its clinical relevance to AAA remains unknown. In this study, 205 AAA patients and 205 age- and sex-matched controls were included to detect the serum ATG4B levels. Meanwhile, abdominal aortic specimens from 24 AAA patients and 6 human organ donors were collected to evaluate the mRNA and in situ protein expression of ATG4B. We observed significantly higher ATG4B mRNA and protein expression levels in AAA group compared to those in control group, with a positive correlation between mRNA levels and serum/in situ protein levels (serum, r = 0.518, P = 0.010; in situ, r = 0.453, P = 0.026). Serum ATG4B exhibited the diagnostic potential for AAA (AUC = 0.702, sensitivity = 75.6%) and intraluminal thrombus recognition (AUC = 0.602, sensitivity = 67.9%). Logistic regression revealed a significant association between elevated serum ATG4B and an increased risk of AAA and intraluminal thrombus formation. Deceased patients displayed higher baseline serum ATG4B levels, which could predict postoperative mortality (HR = 1.028, 95%CI = 1.007-1.049, P = 0.009, AUC = 0.612, sensitivity = 84.6%). The bioinformatics analysis suggested that ATG4B may modulate cellular autophagy and influence pathways associated with inflammation, lipid metabolism, or apoptosis, thereby contributing to the occurrence and development of AAA. The drug-gene interaction network identified 13 potential therapeutic drugs targeting ATG4B. In conclusion, ATG4B may serve as a promising biomarker for the diagnosis and prognostic assessment of AAA patients and play a key role in the pathogenesis of AAA., Competing Interests: Declarations. Ethics approval and consent to participate: Ethics approval was approved by the ethics committee of the First Hospital of China Medical University (Shenyang, China, Ethical Approval Number: [2020]146), and written informed consent was obtained from each patient. Conflict of interest: All authors declare that they have no competing interests., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2025
- Full Text
- View/download PDF